{{Rsnum
|rsid=9299075
|Gene=PTPRD
|Chromosome=9
|position=8798347
|Orientation=plus
|GMAF=0.2599
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 7.1 | 46.0 | 46.9
| HCB | 3.0 | 28.9 | 68.1
| JPT | 11.8 | 41.8 | 46.4
| YRI | 9.0 | 48.6 | 42.4
| ASW | 5.3 | 47.4 | 47.4
| CHB | 3.0 | 28.9 | 68.1
| CHD | 3.8 | 27.6 | 68.6
| GIH | 8.9 | 42.6 | 48.5
| LWK | 3.6 | 50.0 | 46.4
| MEX | 3.4 | 27.6 | 69.0
| MKK | 12.9 | 37.4 | 49.7
| TSI | 5.9 | 36.3 | 57.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs9299075
|Name_s=
|Gene_s=PTPRD
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00005. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109452
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs9299075
|overall_frequency_n=99
|overall_frequency_d=128
|overall_frequency=0.773438
|n_genomes=52
|n_genomes_annotated=0
|n_haplomes=85
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}